ArticleFrontiers in immunology2022

Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.

Xiang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.